Nathan J Bowen
Overview
Explore the profile of Nathan J Bowen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie Z, et al.
Br J Cancer
. 2023 Jul;
129(5):884-894.
PMID: 37474721
Background: It is imperative to develop novel therapeutics to overcome chemoresistance, a significant obstacle in the clinical management of prostate cancer (PCa) and other cancers. Methods: A phenotypic screen was...
2.
Bai L, Li X, Yang Y, Zhao R, White E, Danaher A, et al.
Transl Oncol
. 2023 Jun;
34:101707.
PMID: 37271121
Chemoresistance is a major obstacle in the clinical management of metastatic, castration-resistant prostate cancer (PCa). It is imperative to develop novel strategies to overcome chemoresistance and improve clinical outcomes in...
3.
Hewa Bostanthirige D, Komaragiri S, Joshi J, Alzahrani M, Saini I, Jain S, et al.
Oncoscience
. 2021 Apr;
8:14-30.
PMID: 33884281
Inhibitor of differentiation 4 (Id4), a member of the helix-loop-helix family of transcriptional regulators has emerged as a tumor suppressor in prostate cancer. In this study we investigated the effect...
4.
Du F, Li Y, Zhang W, Kale S, McFerrin H, Davenport I, et al.
Tumour Biol
. 2016 Mar;
37(8):11147-11162.
PMID: 26935058
Patients with advanced epithelial ovarian cancer often experience disease recurrence after standard therapies, a critical factor in determining their five-year survival rate. Recent reports indicated that long-term or short-term survival...
5.
Pannu V, Rida P, Ogden A, Turaga R, Donthamsetty S, Bowen N, et al.
Oncotarget
. 2015 Mar;
6(8):6076-91.
PMID: 25788277
Human breast tumors harbor supernumerary centrosomes in almost 80% of tumor cells. Although amplified centrosomes compromise cell viability via multipolar spindles resulting in death-inducing aneuploidy, cancer cells tend to cluster...
6.
Chinaranagari S, Sharma P, Bowen N, Chaudhary J
Methods Mol Biol
. 2014 Nov;
1238:125-40.
PMID: 25421658
Prostate cancer is a major health burden within the ever-increasingly aging US population. The molecular mechanisms involved in prostate cancer are diverse and heterogeneous. In this context, epigenetic changes, both...
7.
Patel D, Knowell A, Korang-Yeboah M, Sharma P, Joshi J, Glymph S, et al.
Mol Endocrinol
. 2014 Jun;
28(8):1239-53.
PMID: 24921661
Prostate cancer (PCa) is the most commonly diagnosed cancer in men in the Western world. The transition of androgen-dependent PCa to castration-resistant (CRPC) is a major clinical manifestation during disease...
8.
Liu Y, Bowen N, Matyunina L, McDonald J, Prausnitz M
Int J Hyperthermia
. 2012 May;
28(4):349-61.
PMID: 22621736
Purpose: Heterogeneous bioeffects have been reported in previous studies of ultrasound-mediated gene delivery. The goal of this study is to identify the differences between cells that take up plasmid DNA...
9.
Wang L, Mezencev R, Bowen N, Matyunina L, McDonald J
Mol Cell Biochem
. 2011 Dec;
363(1-2):257-68.
PMID: 22160925
Increasing evidence supports the existence of a subpopulation of cancer cells capable of self-renewal and differentiation into diverse cell lineages. These cancer stem-like or cancer-initiating cells (CICs) also demonstrate resistance...
10.
Huda A, Tyagi E, Marino-Ramirez L, Bowen N, Jjingo D, Jordan I
PLoS One
. 2011 Nov;
6(11):e27513.
PMID: 22087331
Experimentally characterized enhancer regions have previously been shown to display specific patterns of enrichment for several different histone modifications. We modelled these enhancer chromatin profiles in the human genome and...